116 related articles for article (PubMed ID: 11486155)
21. Cisapride and patient information leaflets.
Sukkari SR; Sasich LD
CMAJ; 2001 May; 164(9):1276-8; author reply 1278-9. PubMed ID: 11341134
[No Abstract] [Full Text] [Related]
22. Comparison of adverse drug reaction reporting in veterinary and human medicine.
Bukowski JA; Wartenberg D
J Am Vet Med Assoc; 1996 Jul; 209(1):40-5. PubMed ID: 8926206
[No Abstract] [Full Text] [Related]
23. Turning over a new leaf versus shaking the tree.
Stewart-Amidei C
J Neurosci Nurs; 2004 Oct; 36(5):243. PubMed ID: 15524238
[No Abstract] [Full Text] [Related]
24. Reporting adverse vaccine events.
O'Rourke K
J Am Vet Med Assoc; 2003 Sep; 223(6):753-4. PubMed ID: 14507079
[No Abstract] [Full Text] [Related]
25. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
[TBL] [Abstract][Full Text] [Related]
26. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
27. The United States Pharmacopeia Veterinary Practitioners' Reporting Program.
Meyer EK; Becker SC
J Am Vet Med Assoc; 1996 Feb; 208(3):361-3. PubMed ID: 8575965
[No Abstract] [Full Text] [Related]
28. Cause and effect? Assessing postmarketing safety studies as evidence of causation in products liability cases.
Shea LL; Hanson A; Guglielmetti TM; Levy K
Food Drug Law J; 2007; 62(3):445-72. PubMed ID: 17915388
[No Abstract] [Full Text] [Related]
29. Adverse drug reactions, MedWatch reporting and medical student education.
Lewis LD; Nierenberg DW
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):93-5. PubMed ID: 12642972
[No Abstract] [Full Text] [Related]
30. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Clin Pharm; 1993 Jul; 12(7):529-32. PubMed ID: 8354041
[No Abstract] [Full Text] [Related]
31. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
O'Reilly JT
Food Drug Law J; 2007; 62(3):559-72. PubMed ID: 17915397
[No Abstract] [Full Text] [Related]
32. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
33. MEDWatch: medical products reporting program.
Minarik PA
Clin Nurse Spec; 1994 Mar; 8(2):74, 68. PubMed ID: 7882246
[No Abstract] [Full Text] [Related]
34. Journals, FDA announce steps to encourage ADR reporting.
Thompson CA
Am J Hosp Pharm; 1994 Apr; 51(8):966-8, 974. PubMed ID: 8037224
[No Abstract] [Full Text] [Related]
35. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
36. Use of spontaneous reporting system data.
Andreadis NA; Schirmer RG
Arch Intern Med; 1992 Jul; 152(7):1527-9. PubMed ID: 1627034
[No Abstract] [Full Text] [Related]
37. Adverse event reporting: essential for science and public trust.
Verma IM
Mol Ther; 2001 Aug; 4(2):83. PubMed ID: 11482977
[No Abstract] [Full Text] [Related]
38. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
Buck ML
Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
[No Abstract] [Full Text] [Related]
39. Making a difference.
Nat Biotechnol; 2009 Apr; 27(4):297. PubMed ID: 19352347
[No Abstract] [Full Text] [Related]
40. Communicating with patients about drug interactions.
Bowers R
J Tenn Med Assoc; 1994 Jan; 87(1):18. PubMed ID: 8145553
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
